Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Study to Evaluate Socazolimab for Recurrent or Metastatic Cervical Cancer

X
Trial Profile

A Pivotal Study to Evaluate Socazolimab for Recurrent or Metastatic Cervical Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Socazolimab (Primary)
  • Indications Cervical cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2021 According to a Sorrento Therapeutics media release, the company's license partner, China Oncology Focus Limited (COF) Lee's Pharmaceutical, has submitted a NDA (new drug application) for Socazolimab for the greater China territory to treat recurrent or metastatic cervical cancer. The NDA application has been accepted by China NMPA.
    • 12 Mar 2021 New trial record
    • 07 Mar 2021 According to a Sorrento Therapeutics media release, Lees Pharm expects to file the New Drug Application for Socazolimab in recurrent or metastatic cervical cancer in the second quarter of 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top